^
    1d
    IL-8-Induced Tumor Self-Rampart Spatially Confines Oncolytic Virotherapy in Glioblastoma. (PubMed, Neuro Oncol)
    Glioblastoma mounts a spatial self-protective defense through IL-8-driven TSR formation that restricts oncolytic virus spread. IL-8 functions as both a pharmacodynamic biomarker and a therapeutic target, and its inhibition provides a rational strategy to overcome resistance and optimize GBM virotherapy.
    Journal • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    YSCH-01 • reparixin (DF 1681Y)
    2d
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. (clinicaltrials.gov)
    P1/2, N=30, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    2d
    A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | N=27 --> 0 | Enrolling by invitation --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide
    3d
    Oncolytic virotherapy: molecular mechanisms, delivery strategies, and translational insights. (PubMed, Crit Rev Oncol Hematol)
    We highlight trials where OVs prime checkpoint response (e.g., DNX-2401→pembrolizumab in recurrent glioblastoma) and where vector design (e.g., TK-deleted vaccinia, CG0070) or payloads (e.g., IFNβ, NIS) drive measurable benefit. We conclude with actionable priorities, patient selection by IFN-pathway competence, receptor-tropism panels, and rational OV-ICI sequencing, to accelerate durable responses.
    Review • Journal
    |
    IFNB1 (Interferon Beta 1)
    |
    Keytruda (pembrolizumab) • cretostimogene grenadenorepvec (CG0070) • tasadenoturev (DNX-2401)
    8d
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions. (PubMed, Cancers (Basel))
    Nadofaragene firadenovec, a recombinant adenovirus delivering interferon alpha-2b (IFNα2b), is the first FDA-approved gene therapy for BCG-unresponsive NMIBC with carcinoma in situ (CIS)...Cretostimogene grenadenorepvec (CG0070), an oncolytic vector, demonstrated a 47% 6-month CR rate in a phase II study (NCT02365818). Detalimogene voraplasmid (EG-70), a nonviral gene therapy, demonstrated a 47% 6-month CR in a phase I/II study (NCT04752722). Future advances are likely to focus on patient selection, novel vectors, and combination strategies to improve treatment outcomes. Gene therapy represents a significant addition to the bladder cancer treatment landscape by offering bladder-sparing alternatives where conventional therapies are limited.
    Review • Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Adstiladrin (nadofaragene firadenovec-vncg) • cretostimogene grenadenorepvec (CG0070) • detalimogene voraplasmid (EG-70)
    9d
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=12, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> May 2026
    Trial completion date • Trial primary completion date
    13d
    A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Adze Biotechnology Australia Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    14d
    ATLAS-IT-05: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (clinicaltrials.gov)
    P2, N=23, Completed, Lytix Biopharma AS | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2025
    Trial completion • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
    16d
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Sep 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    2ms
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov)
    P1/2, N=126, Recruiting, Maastricht University Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    MSK-IMPACT
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506
    2ms
    diSArm: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (clinicaltrials.gov)
    P1/2, N=50, Completed, Armata Pharmaceuticals, Inc. | Trial primary completion date: Jan 2024 --> Nov 2024
    Trial primary completion date
    2ms
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=12, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial primary completion date: Apr 2026 --> Sep 2025
    Trial primary completion date